Literature DB >> 34329732

Pulsed field catheter ablation in atrial fibrillation.

Luigi Di Biase1, Juan Carlos Diaz2, Xiao-Dong Zhang2, Jorge Romero2.   

Abstract

Catheter ablation (CA) has become the mainstay therapy for the maintenance of sinus rhythm in patients with atrial fibrillation (AF), with pulmonary vein isolation (PVI) the most frequently used treatment strategy. Although several energy sources have been tested (including radiofrequency, cryothermal and laser), these are not devoid of safety issues and in many instances effectiveness is dependent on operator experience. Pulsed field ablation (PFA) is a novel energy source by which high-voltage electric pulses are used to create pores in the cellular membrane (i.e., electroporation), leading to cellular death. The amount of energy required to produce irreversible electroporation is highly tissue dependent. In consequence, a tailored protocol in which specific targeting of the atrial myocardium is achieved while sparing adjacent tissues is theoretically feasible, increasing the safety of the procedure. While large scale clinical trials are lacking, current clinical evidence has demonstrated significant efficacy in achieving durable PVI without ablation related adverse events.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Complications; Cryoenegy; Electroporation; Energy source; Pulsed field ablation; Radio-frequency

Mesh:

Year:  2021        PMID: 34329732     DOI: 10.1016/j.tcm.2021.07.006

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   8.049


  2 in total

Review 1.  [Catheter ablation : Developments and technique selection].

Authors:  L Yahsaly; J Siebermair; R Wakili
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2022-02-18

Review 2.  Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.

Authors:  Nana Zhang; Zhuoqun Li; Xuan Han; Ziyu Zhu; Zhujun Li; Yan Zhao; Zhijun Liu; Yi Lv
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.